Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter

AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients

The submission is supported by positive results from the Phase 3 AMPLIFY trial

Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines

Vasograin Plus represents a major advancement in the treatment of migraine

Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure

Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint

Aster DM Healthcare to build Rs. 580 crore crore hospital in Bengaluru

This will be Aster’s fifth hospital in Bengaluru

Beta-HPV can directly cause skin cancer in immunocompromised people

cSCC is one of the most common cancers in the U.S. and globally

Johnson & Johnson submits additional data to FDA on psoriatic arthritis

The submission is supported by results from the Phase 3b APEX study

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

India Formulation sales accounted for 34.2% of total consolidated sales for the quarter

Zydus completes acquisition of 85.6% stake in Amplitude Surgical

iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025

A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide